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Prevalence and distribution of G6PD 
deficiency: implication for the use 
of primaquine in malaria treatment in Ethiopia
Eugenia Lo1*† , Daibin Zhong2†, Beka Raya3, Kareen Pestana1, Cristian Koepfli4, Ming‑Chieh Lee2, 
Delenasaw Yewhalaw3,5 and Guiyun Yan2*
Abstract 
Background: G6PD enzyme deficiency is a common enzymatic X‑linked disorder. Deficiency of the G6PD enzyme 
can cause free radical‑mediated oxidative damage to red blood cells, leading to premature haemolysis. Treatment of 
Plasmodium vivax malaria with primaquine poses a potential risk of mild to severe acute haemolytic anaemia in G6PD 
deficient people. In this study, the prevalence and distribution of G6PD mutations were investigated across broad 
areas of Ethiopia, and tested the association between G6PD genotype and phenotype with the goal to provide addi‑
tional information relevant to the use of primaquine in malaria treatment.
Methods: This study examined G6PD mutations in exons 3–11 for 344 febrile patient samples collected from seven 
sites across Ethiopia. In addition, the G6PD enzyme level of 400 febrile patient samples from Southwestern Ethiopia 
was determined by the CareStart™ biosensor. The association between G6PD phenotype and genotype was exam‑
ined by Fisher exact test on a subset of 184 samples.
Results: Mutations were observed at three positions of the G6PD gene. The most common G6PD mutation across 
all sites was A376G, which was detected in 21 of 344 (6.1%) febrile patients. Thirteen of them were homozygous and 
eight were heterozygous for this mutation. The G267+119C/T mutation was found in 4 (1.2%) individuals in South 
Ethiopia, but absent in other sites. The G1116A mutation was also found in 4 (1.2%) individuals from East and South 
Ethiopia. For the 400 samples in the south, 17 (4.25%) were shown to be G6PD‑deficient. G6PD enzyme level was not 
significantly different by age or gender. Among a subset of 202 febrile patients who were diagnosed with malaria, 
11 (5.45%) were G6PD‑deficient. These 11 infected samples were diagnosed with Plasmodium vivax by microscopy. 
Parasitaemia was not significantly different between the G6PD‑deficient and G6PD‑normal infections.
Conclusions: The prevalence of G6PD deficiency is modest among febrile patients in Ethiopia. G6PD deficiency test‑
ing is thus recommended before administrating primaquine for radical cure of P. vivax infected patients. The present 
study did not indicate a significant association between G6PD gene mutations and enzyme levels.
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Background
Glucose-6-phosphate dehydrogenase (G6PD) is an 
enzyme involved in the pentose monophosphate pathway. 
Deficiency of this enzyme leads to free radical-mediated 
oxidative damage to red blood cells, and in turn causes 
haemolysis. G6PD deficiency is the most common enzy-
matic disorder of red blood cells, affecting 400 million 
people worldwide [1]. It is an X-linked disorder with high 
prevalence particularly in people of African, Asian, and 
Mediterranean descent [1]. In Africa, the most common 
G6PD enzyme-deficient variant is A- [2]. Females with 
G6PD A- heterozygotes have been shown with selective 
advantage against severe malaria [3–5]. By selection, this 
G6PD-deficient trait becomes prevalent (8%) in popula-
tions where malaria is endemic [6].
The prevalence of G6PD deficiency is highly relevant 
to the choice of drug used in anti-malarial treatment [7, 
8]. A number of drugs, such as primaquine, dapsone, 
sulfonamides, quinolones, chloramphenicol, nitrofuran-
toins (antibiotics), and phenazopyridine (analgesics), 
have been described as haemolytic trigger that causes 
haemolytic crisis in G6PD-deficient individuals [9, 10]. 
Primaquine is the recommended treatment drug to elim-
inate Plasmodium vivax hypnozoites and Plasmodium 
falciparum gametocytes, along with the goal to progress 
towards zero malaria transmission in Africa [11–14]. It is 
an ideal agent to be used as primary prophylaxis against 
P. vivax [6]. However, primaquine can also induce oxi-
dative stress causing a spectrum of haemolytic anaemia 
ranging from mild to severe haemolysis in G6PD-defi-
cient individuals [15]. The likelihood of developing hae-
molysis and its severity depends on the level of enzyme 
deficiency, which in turn is determined by the type of 
G6PD variant [16–18].  The risk for haemolytic anaemia 
is particularly high in patients who are treated for P. vivax 
malaria because they are usually given a higher dose of 
primaquine (0.25–0.5 mg in a 14-day treatment regime) 
compared to those treated for P. falciparum (a single dose 
of 0.25 mg on the first day of treatment) [19]. A high dose 
of primaquine (0.5 mg base/kg daily for 14 days) has been 
previously shown to be more effective than a low dose 
(0.25  mg base/kg daily for 14  days) in eliminating pri-
mary blood infection and preventing relapse episodes in 
P. vivax patients [11, 20–22]. However, the lack of G6PD 
level information, inaccurate methods of screening G6PD 
deficiency, and the uncertainty in the safety of a single 
versus long-term primaquine dosage pose risk to malaria 
patients when treat with primaquine.
The gene encoding the G6PD protein consists of 13 
exons and 12 introns [23] and is located on the X chro-
mosome. This gene is highly polymorphic with nearly 
160 mutations at the DNA level that are potentially asso-
ciated with G6PD deficiency [24]. The frequency of these 
mutations varies among populations and countries. For 
instance, mutation S188F, sometimes called the Mediter-
ranean mutation, is most prevalent among individuals 
from the Middle East [25]. Mutations C131G and G487A 
that were common in Dhaka, Bangladesh appear to be 
linked to G6PD deficiency by affecting NADP binding or 
disrupting the protein structure [26]. The G6PD genetic 
variants were relatively homogeneous in America, Africa, 
and western Asia compared to those in East Asia and 
Oceania. In North America, Africa, Yemen and Saudi 
Arabia, G6PD*A- variant is predominant among popu-
lations. By contrast, G6PD variants are highly heteroge-
neous in East Asia such as China and the Asia–Pacific 
where no single variant predominates [6, 27].
Ethiopia is one of the few African countries where 
P. vivax and P. falciparum coexist, and account for 60% 
and 40% of the malaria cases, respectively [28]. G6PD 
deficiency was previously estimated to be as high as 
17% in southwestern Ethiopia based on the CareStart™ 
fluorescence spot test [29]. The mutation A376G that 
constitutes G6PD*A- variant accounted for nearly 23% 
of the malaria patients. Other mutations including 
rs782669677 (535 G->A), rs370658483 (485 + 37 G->T), 
and chrX:154535443 (C->T) were recently observed in 
the same geographical region through an investigation 
of a short segment of the G6PD gene [30]. These muta-
tions did not appear to disrupt function or structure of 
the G6PD protein [30]. In this study, the prevalence 
and distribution of G6PD mutations were investigated 
among a large number of febrile patients across broad 
areas of Ethiopia. For a subset of samples, the association 
between G6PD genetic mutations and enzyme level was 
examined. Malaria parasitaemia and demographic fea-
tures in the G6PD deficient and non-deficient individuals 
were characterized.
Methods
Study site and sample collection
A total of 344 blood samples were collected in seven 
study sites including Bure and Mankush from the north, 
Metehara and Shewa Robit from the east, as well as Hal-
aba, Agaro, and Jimma from the southwest part of Ethio-
pia during 2013 to 2016 (Fig.  1). These study sites have 
high elevations, ranging from 1680  m to 2010 m above 
sea level. Malaria transmission is seasonal and unsta-
ble, with frequent epidemics in these areas. In Bure, 
Mankush, Metehara, Shewa Robit and Halaba, blood 
samples from 160 febrile patients visiting the health cent-
ers or hospitals were collected and these samples were 
included in G6PD genotyping. In Agaro and Jimma, 
blood samples from 184 febrile patients were collected 
and these samples were included in both G6PD geno-
typing and phenotyping assays. Genomic DNA was 
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extracted from dried blood spots by the Saponin/Chelex 
method [31] and eluted in a total volume of 200 μl Tris–
EDTA (TE) buffer.
Molecular genotyping and G6PD gene sequencing
For G6PD genotyping, four PCR assays were conducted 
to determine the G6PD gene mutations of exon 3–11 
(Table 1). For each PCR assay, water was used in a sepa-
rate reaction as a negative control. PCR amplification 
was conducted in a 20  μl reaction mixture containing 
2 μl of genomic DNA (~ 50 ng/μl), 10 μl of 2 × Maxima 
SYBR Green qPCR Master Mix (Thermo Fisher) and 0.3 
uM of each forward and reverse primers. Amplifications 
were performed with an initial denaturation at 94 °C for 
3 min, followed by 38 cycles at 94  °C for 30 s, 55  °C for 
30  s and 72  °C for 60  s, with a final 6  min extension at 
72  °C. Amplified PCR products were purified with 2 
U Exonuclease I and 2U Shrimp Alkaline Phosphatase 
(Thermo Fisher) at 37 °C followed by 15 min incubation 
at 80  °C to deactivate the enzymes. Purified PCR prod-
ucts were sequenced in both directions on an ABI 3730xl 
DNA analyzer (Genewiz Inc., La Jolla, CA). Sequences 
were analysed using Codon Code Aligner Program ver-
sion 7.0.1 (CodonCode Corporation, Centerville, MA). 
All sequences were aligned to the NCBI reference 
sequence (NG_009015.2) to verify the specificity of the 
PCR products. Samples with poor sequencing quality 
or showed singleton mutations were re-amplified and 
sequenced.
G6PD phenotype measurement
G6PD enzyme level was measured by CareStart™ 
Biosensor (Access Bio, Seoul, Korea) on 400 clini-
cal samples collected from Agaro and Jimma, Ethiopia 
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Fig. 1 Map showing the distribution of the seven study sites in Ethiopia
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following the manufacturer’s instruction. For each par-
ticipant, demographic information was recorded by 
questionnaire. Briefly, for each sample, a G6PD test 
strip with two drops (20–30  μl) of finger-prick whole 
blood was inserted into the biosensor at room tem-
perature. The biosensor took about 4–5 min to indicate 
the G6PD reading and was automatically recorded. The 
G6PD enzyme activity was expressed in U/dl unit. A 
blank control was used to calibrate the G6PD biosen-
sor to ensure the reading was zero before the next sam-
ple measurement. For each sample that was measured 
for G6PD enzyme level, haemoglobin level was also 
estimated using HemoCueHb 201 + analyzer follow-
ing the manufacturer’s instruction. G6PD enzyme level 
was normalized by the concentration of haemoglobin 
(i.e. unit of G6PD enzyme per gram of haemoglobin, 
U/gHb). G6PD normal and deficient individuals were 
categorized into two class in male and three classes in 
female following the WHO classification [11, 32]. The 
adjusted male median (AMM) G6PD activity, defined 
as the median G6PD activity of all male participants 
after excluding samples with less than 10% of the over-
all median activity, was calculated. For male, class I is 
G6PD deficient with < 30% of the AMM activity and 
class II is normal with > 30% of the AMM activity. For 
female, G6PD activity < 30%, 30–80%, and > 80% of the 
AMM activity are considered as G6PD deficient, inter-
mediate, and normal, respectively [32].
Data analysis
All statistical analyses were performed using JMP Pro 
12.2.0 software (SAS Institute Inc. 2015). The Mann–
Whitney U test was used for non-parametric compari-
sons, and Student’s t test and one-way analysis of variance 
for parametric comparisons. Fisher’s exact test was used 
to examine the association between G6PD genotype and 
phenotype at the confidence level of P = 0.05.
Results
Frequency of G6PD gene mutations
A total of 344 febrile patients collected from seven study 
sites in Ethiopia were sequenced for the G6PD exons 
3–11. The common mutation A376G (rs1050829, A→G) 
was detected in 21 (6.1%) of the individuals, of which 
ten were homozygote for G376 and eight were heterozy-
gotes (Table  2). This mutation was found in all study 
sites except Shewa Robit (East Ethiopia). Other muta-
tions including G267+119C/T (rs782000110, C→T) 
and G1116A (rs2230036, G→A) were detected in 4 
(1.2%) and 4 (1.2%) individuals, respectively (Table  2). 
The G267+119C/T (rs782000110, C→T) mutation was 
found exclusively in Agaro and Jimma (South Ethiopia); 
whereas the G1116A (rs2230036, G→A) mutation was 
found in both East and South Ethiopia. The absence of 
these mutations in the north could be due to small sam-
ple size (N = 48; Table 2). All these three mutations were 
found separately in different individuals. For other previ-
ously reported positions [30] such as G202A at exon 4, 
chrX:154535443 C-T at exon 5, and C563T at exon 6, no 
mutations were detected among the samples (Table 2). It 
is noted that the G6PD sequences presented in this study 
did not cover the two intronic positions (rs370658483, 
485 + 37 G→T and rs782669677, 535 G→A) that were 
previously shown to be polymorphic but rare among the 
Ethiopians [30].
Among the 344 febrile patients, a subset of 184 individ-
uals from Agaro and Jimma (South Ethiopia) were ana-
lysed further by demography and malaria infection. For 
the three positions A376G, G267 + 119C-T, and G1116A 
where mutations were observed, the mutation frequency 
ranged from 0.9 to 5.1% in males and 2.3 to 5.6% in 
females. No significant difference was observed in the 
mutation frequency between males and females (one-
tailed t test, P = 0.47; Table 3). As expected, only hemizy-
gotes (i.e., individuals with only one allele of the G6PD 
gene) were observed in the male patients, whereas both 
Table 1 PCR primer sequences and amplicon size of G6PD gene
Primer position can be referred to NCBI accession no. NG_009015.2
PCR pair Primer name Primer sequence (5′–3′) Primer position PCR product 
(bp)
Coding region 
(bp)
Exon coverage
1 6284F CAA GGA GTG ATT TGG GCA AT 6284
6755R AGA GCA AAA CTC CGT CTC CA 6755 472 120 Exon 3
2 D‑6F AAT CTC GGG GCT CTT CTG TCTG 16,237
D‑1170R GCA ACG GCA AGC CTT ACA TCTG 17,422 1185 365 Exon 4–6
3 D‑1880F CTT CGG GAG GGA CCT GCA GAG 18,107
D‑2865R GTG GTG ACT TCT CCG GGG TTGA 19,114 1007 379 Exon 7–9
4 G6‑5F CCT GAG GGC TGC ACA TCT 19,356
G6‑5R GTG TCT TGC TGA TGC CAC TG 20,096 740 423 Exon 10–11
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heterozygotes and homozygote recessive were observed 
in the female patients.
Among the 344 febrile patients, 158 (45.9%) were diag-
nosed with malaria. Of these 158 malaria patients, the 
mutation frequency of the three G6PD gene positions 
(A376G, G267 + 119C-T, and G1116A) ranged from 0.6 
to 4.4% (Table 4). Between the malaria-infected and non-
infected patients, we found no significant difference in 
the mutation frequency for A376G, G267 + 119C-T and 
G1116A (one-tailed t-test, P = 0.15; Table  4). Likewise, 
no significant difference was observed in the mutation 
frequency when the samples were stratified by age, i.e., 
under 5, 5–15 and above 14 years old, despite a marked 
difference in sample size among the three age groups 
(Additional file 1: Table S1).
Measurement of G6PD enzyme activity
Based on the WHO guidelines [11, 32], the AMM G6PD 
activity of all male participants after excluding samples 
with less than 10% of the overall median activity was 6.25 
U/gHb. Thus, patients with value < 1.88 U/gHb (i.e., < 30% 
of the AMM activity) were considered as G6PD deficient 
in both male and female. Among the 400 patients from 
Agaro and Jimma (southwestern Ethiopia), 17 (4.3%) 
had G6PD activity < 1.88 U/gHb and were considered as 
G6PD deficient. One of these 17 patients was under the 
age of 5, one was aged 5–14, and the remaining were 
above the age of 14 (Fig.  2a). No significant difference 
was observed in the distribution of G6PD level among 
the three age groups despite the remarkable difference in 
sample size (Fig. 2a).
Likewise, no significant difference was observed in the 
distribution of G6PD enzyme level between males and 
females (average G6PD level = 6.3 ± 2.5 U/gHb for both 
gender; one-tailed t-test, P = 0.56; Fig.  2b). For male, 
G6PD level ranged from 0.62 to 20.16 U/gHb, and 10 out 
of 184 (5.4%) were G6PD deficient. For female, G6PD 
level ranged from 0.76 to 13.86 U/gHb; 7 out of 136 
(5.2%) were G6PD deficient, 47 (34.6%) were G6PD inter-
mediate, and 82 (60.3%) were G6PD normal (Fig. 2b). The 
prevalence of low G6PD was not significantly different 
between the two groups.
Of the 158 patient samples (95 males and 63 females) 
that were diagnosed with malaria, 11 (6.9%) were con-
sidered as G6PD deficient (Fig. 3). For the non-infected 
individuals, 5 out of 49 (8.2%) were considered as G6PD 
deficient. Despite the contrast in sample size, there was 
no significant difference in the distribution of G6PD 
level between these two groups of individuals (one-tailed 
t-test, P = 0.05; Fig.  3). Among the malaria-infected 
patients, no significant difference was detected in the 
microscopic-based parasitaemia between the low and 
normal G6PD individuals (one-tailed t-test, P = 0.06; 
Fig. 4). Two of the 158 malaria patients were diagnosed 
with P. falciparum, whereas the rest with P. vivax infec-
tions. The two P. falciparum-infected patients had a 
G6PD level of 4.87 and 5.20 U/gHb, respectively, and 
were considered as G6PD normal.
Table 3 Distribution of  three G6PD genotypes where  mutations were detected among  male and  female individuals 
in Jimma and Agaro, southwestern Ethiopia
Due to the lack of demographic information, samples from other study sites were not included in this analysis
Gender N G6PD genotype
A376G G267+119C/T G1116A
Wild type Mutant Wild type Mutant Wild type Mutant
Male 118 112
(94.9%)
6 (G/G)
(5.1%)
117
(99.1%)
1 (T/T)
(0.9%)
116
(98.3%)
2 (A/A)
(1.7%)
Female 89 84
(94.4%)
2 (G/G); 3 (A/G)
(5.6%)
87
(97.7%)
1 (T/T); 1 (C/T)
(2.3%)
89
(100%)
0
Table 4 Distribution of G6PD genotypes among non-infected and malaria-infected individuals in Ethiopia
Type of patients N G6PD genotype
A376G G267+119C/T G1116A
Wild type Mutant Wild type Mutant Wild type Mutant
Non‑malaria 49 45
(91.8%)
2 (G/G); 2 (A/G)
(8.2%)
48
(97.9%)
1 (C/T)
(2.1%)
49
(100%)
0
Malaria‑infected 158 151
(95.6%)
6 (G/G); 1 (A/G)
(4.4%)
157
(99.4%)
2 (T/T)
(0.6%)
157
(99.4%)
2 (A/A)
(0.6%)
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Association between genotype and phenotype
The G6PD genotype was compared with phenotype for a 
subset of 184 samples collected from Agaro and Jimma 
(Table 2). The G6PD enzyme level was compared among 
the different genotypes (Fig. 5). Of the 174 samples that 
were indicated with no G6PD mutations, one sample had 
a G6PD level of 1.69 U/gHb and was considered as G6PD 
deficient (Fig. 5). For the six samples that had mutation 
A376G (G/G and A/G), G6PD level ranged from 5.38 to 
9.77 U/gHb and all were considered as G6PD normal. 
For the two samples with mutation G267 + 119C-T (T/T 
and C/T), G6PD level was normal (5.62 and 10.17 U/gHb, 
respectively). Likewise, the two samples with mutation 
G1116A (A/A) also had normal G6PD level (6.61 and 
9.17 U/gHb, respectively; Fig.  5). Thus, the mutations 
observed in A376G, G267 + 119C-T, and G1116A did not 
associate with low G6PD, despite the limited number of 
samples in the present study.
Discussion
To date, 8-aminoquinolines, primaquine and tafenoquine 
are the only effective drugs that eradicate the dormant 
liver stages of P. vivax and avoid relapse. However, pri-
maquine and tafenoquine can cause acute haemolytic 
anaemia in individuals with low G6PD enzyme level. 
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The issue of low G6PD has also impacted the use of pri-
maquine as gametocytocide for P. falciparum malaria. 
In the Greater Mekong Subregion, G6PD deficiency has 
been reported to be common in males with a prevalence 
of 7.3% to 18.8% based on the CareStart™ Fluorescent 
Spot Test [33]. In Bangladesh, a prevalence of 17.4% 
(173/995) for G6PD deficiency (< 60% of the adjusted 
male median G6PD activity) was reported using standard 
UV spectrophotometry [34]. Using the CareStart™ G6PD 
test kit, this study identified a prevalence of 4.3% G6PD 
deficiency among febrile patients in southwestern Ethio-
pia based on a threshold cutoff of 1.88 U/g Hb (i.e. < 30% 
of the AMM G6PD activity). This prevalence rate was 
slightly higher than a previous report of 1.4% G6PD defi-
ciency in other parts of Ethiopia using the same device 
and cutoff threshold [35], but much lower than those 
reported in Asia [33, 34]. Such a pattern indicated differ-
ences not only at the continental but also regional level in 
the distribution of G6PD deficiency.
Some earlier studies demonstrated an association 
of low G6PD level with a low risk of asymptomatic P. 
falciparum infections [36]; whereas others showed 
no association of G6PD deficiency with total severe 
malaria or diseases caused by malaria parasite spe-
cies [37]. While the potential association between low 
G6PD level and host immunity is not tested in the pre-
sent study because of sampling bias towards malaria 
patients, malaria-infected individuals with normal 
G6PD enzyme level indicated a slightly but non-sig-
nificantly higher parasite density than those with low 
G6PD enzyme. Association analyses did not reveal a 
significance difference in G6PD enzyme level between 
males and females, as well as among various age 
groups. While most of the populations in southwestern 
Ethiopia belong to either the Amhara or Oromo tribes, 
ethnicity data of the included patients is not available 
for us to formally test the association between ethnicity 
and G6PD enzyme level.
More than 400 allelic variants of the G6PD gene 
have been reported [10, 18, 26, 38, 39]. Among the 344 
Ethiopian samples, three SNPs were detected between 
exon 3 and exon 11 of the G6PD gene, including codon 
A376G, one of the most common G6PD mutations with 
an average frequency of 6.1% across the study sites. This 
mutation has also been previously reported in in Ethio-
pia [30, 35, 40]. The other two mutations G267+119C/T 
and G116A were detected with relatively low frequen-
cies in this study. Based on the analyses of a subset of 
184 samples, none of these mutations was associated 
with low G6PD enzyme level. One possible explana-
tion could be only a small number of low G6PD sam-
ples were sequenced. The association between G6PD 
genotype and phenotype merits further verification 
with broader samples. Another possibility is that there 
could be other codons of the G6PD gene that we did 
not sequence in this study. Also, G6PD phenotype 
was only measured by one but not multiple biosen-
sors or device for comparison. The CareStart™ G6PD 
rapid test kit used in this study has the advantages of 
being small and handy, easy to perform, produce results 
within a few minutes, and can be used without electric-
ity or specific equipment. It is affordable and can detect 
G6PD enzyme activity at a very low level [41]. Com-
pared with the gold standard photospectrometric assay, 
the sensitivity and specificity of the CareStart™ test kit 
are 90–100% and 84.8–100%, respectively [33, 41, 42], 
although a low sensitivity was also reported when used 
on individuals with G6PD enzyme activity < 30% [43, 
44]. Though this CareStart™ G6PD test kit represents 
a significant improvement for quantitative diagnosis of 
G6PD level over previous models, the accuracy of its 
measurement still requires further validation before 
clinical deployment. It is also noteworthy that the sam-
ples included in the present study were febrile patients 
instead of the general population, and that such sam-
pling could bias with a high number of malaria-infected 
individuals. Thus, this study is limited to inferring the 
distribution of G6PD level between non-malaria and 
malaria-infected samples rather than the rate of malaria 
infection between normal and low G6PD individuals.
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Conclusion
Based on G6PD genotyping, the present study revealed 
a modest prevalence of G6PD deficiency among febrile 
patients across Ethiopia. A routine testing for G6PD 
deficiency prior to administrating primaquine for radi-
cal cure of P. vivax infected patients is recommend in 
Ethiopia and other Africa countries. G6PD genotype 
was not significantly associated with G6PD phenotype. 
Nevertheless, this association merits further testing 
with broader samples. Future study should also com-
pare G6PD measurement among different devices with 
the CareStart™ biosensor to validate accuracy before 
clinical deployment in Ethiopia as well as other malari-
ous countries.
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